Introduction
============

Sarcomatoid differentiation (SD) in renal cell carcinoma (RCC) is an indicator of poor prognosis[@b1-cmar-10-5339],[@b2-cmar-10-5339] and is more likely to present with advanced disease at first presentation.[@b1-cmar-10-5339],[@b3-cmar-10-5339]--[@b7-cmar-10-5339] Sarcomatoid RCC (sRCC) was not considered a separate RCC type currently, since it can be observed across all histological types in either clear-cell RCC (ccRCC) or nonclear-cell RCC (ncRCC).[@b8-cmar-10-5339]--[@b11-cmar-10-5339] Transition from epithelial to mesenchymal cells has been proposed as a potential mechanism for the development of SD in RCC.[@b1-cmar-10-5339],[@b9-cmar-10-5339],[@b12-cmar-10-5339] Histologically, it presents features of sarcoma, with atypical spindle-like cells and/or malignant-appearing giant cells interposed with RCC components.[@b9-cmar-10-5339] Although sRCC is a rare morphotype with a low incidence rate of 1%--8% of all RCCs,[@b3-cmar-10-5339] but it has extensive associations with poor clinical outcomes with a low median survival of \<1 year.[@b3-cmar-10-5339],[@b9-cmar-10-5339],[@b13-cmar-10-5339] Despite good effects of surgical treatments for patients with localized RCC[@b14-cmar-10-5339] and new drugs for systemic therapies including targeted therapies against vascular endothelial growth factor (VEGF) and mammalian target of rapamycin pathways for advanced patients who demonstrate better survival,[@b13-cmar-10-5339],[@b15-cmar-10-5339],[@b16-cmar-10-5339] but only few patients with sRCC benefit from systemic therapies.[@b8-cmar-10-5339],[@b13-cmar-10-5339],[@b17-cmar-10-5339]--[@b19-cmar-10-5339]

Several clinicopathological characteristics were reported to be associated with the poor prognosis, and more recent studies have focused on molecular and genomic characteristics of sRCC[@b1-cmar-10-5339],[@b2-cmar-10-5339],[@b5-cmar-10-5339]--[@b7-cmar-10-5339],[@b9-cmar-10-5339]; however, some risk features were not observed because histological criteria were changed, and a larger proportion of patients with clinical distant metastasis (cM~1~) were in prior studies, most of which included patients from a period of at least a decade earlier. Nowadays, because of wide use of regular physical examination by abdominal imaging technologies, this may contribute to increase in the diagnosis of patients with no clinical distant metastasis (cM~0~), and there exists no commonly accepted prognostic nomogram for clinicians in this new period. So a further investigation for predicting prognostic factors of sRCC is still warranted. We aimed to identify predictors of risk stratification in patients with sRCC treated with surgery to better counsel patients and provide more information regarding clinical trial design.

Materials and methods
=====================

The research complied with the Declaration of Helsinki rules, and this retrospective study was approved by the Ethics Committee of Tongji Hospital, Huazhong University of Science and Technology. The need for informed consent from all patients was waived because this was a retrospective study. All data had no personal identifiers and were kept confidential. All patients diagnosed with RCC confirmed pathologically were reviewed at Tongji Hospital, Huazhong University of Science and Technology between January 2003 and September 2017.

Clinicopathological characteristics
-----------------------------------

The clinical variables included gender, age at surgery, body mass index, symptoms at first presentation, comorbidities and Charlson Comorbidity Index, American Society of Anesthesiologists (ASA) score, TNM stage, and lymph nodes (LNs) status determined by imaging. The TNM stage classification was re-evaluated by two clinicians based on the American Joint Cancer Committee (AJCC), 8th edition (2016).[@b20-cmar-10-5339] Tumor size was defined as the longest dimension of the tumor via preoperative computed tomography (CT)/MRI; tumor stage was confirmed by pathological tumor (pT) stage; status of regional LNs was based on the pathologist's assessment; and all patients underwent evaluation of clinical distant metastasis before surgery, including chest radiography/chest CT and abdominal and pelvic CT/MRI. Bone scan and brain CT/MRI were also offered as clinically indicated. All patients with sRCC underwent radical nephrectomy or cytoreductive nephrectomy, which included removal of the affected kidney together with the perirenal fat; LNs and adrenal dissection were routinely performed when the metastasis was indicated by preoperative imaging and intraoperative suspect. Metastasectomy was not recommended for this group of patients with cM~1~ because of multiple or organ-diffused metastases. In consideration of poor prognosis of this disease, we would not recommend to perform surgical treatment for patients with weak performance status, so all patients in our cohort were in a good performance status (The Eastern Co-operative Oncology Group performance status: 0--1 score) and can get a better recovery after surgery. Because most of patients received continued treatment locally postsurgery, we could not assess the postoperative performance status, so we did not include it into analysis.

Patients with a diagnosis of sRCC, spindled RCC, or RCC with the presence of spindle cells were further selected for analysis and were re-examined. The sRCC presents features similar to sarcoma with atypical spindle-like cells and/or malignant-appearing giant cells interposed with RCC epithelial components.[@b9-cmar-10-5339] The primary characteristics including histological subtypes, tumor necrosis, Ki-67 index of SD, and the percent of SD (%SD) were included into analysis with other clinical variables. Histological subtype was categorized into ccRCC and ncRCC based on AJCC, the Union for International Cancer Control, and the Heidelberg classification system.[@b21-cmar-10-5339],[@b22-cmar-10-5339] ncRCC includes papillary, chromophobe, collecting duct, and unclassified RCC subtypes. Ki-67 index of SD was confirmed by immunohistochemical staining, and it was considered as a continuous and categorical variable with cut-off points of 30% and 50% to analyze. %SD was estimated as Kim et al[@b6-cmar-10-5339] reported through reviewing all of the tumor sections microscopically, then giving an approximate percentage of the presence of SD within the entire tumor. In order to keep repeatability, we just use 25% and 50% as cut-off point to re-assess the %SD. Only two patients showed features of microvascular invasion, so we excluded it from the analysis. Because sarcomatoid and rhabdoid differentiations are incorporated into WHO/International Society Of Urological Patheology grade 4,[@b20-cmar-10-5339] we did not include the nuclear grade.

Patient outcome follow-up
-------------------------

The follow-up evaluation for patients with sRCC comprises abdominal ultrasound/CT/MRI performed every 3--6 months for the first 2 years postsurgery, every 6 months from postoperative 3--5 years, and every 12 months thereafter. The electronic medical record system and computer-based patient's record in our outpatient department were the mainly used methods for follow-up, although other methods were also used such as telephone, letter, or other modes of communication to track the patients' prognosis and the cause of death. The medical history and death certificate were reviewed by two urologists together to determine the cause of death or must be verified with the patient's family if a death certificate cannot be obtained. Overall survival (OS) was the primary end point and was assessed from the date of surgery to date of death or last follow-up. OS was our primary end point in our study not the cancer-specific survival. Although most patients died from RCC, we were unable to verify the cause of death in few cases, since a majority of patients continued surveillance or treatment locally after the surgery in our center.

Statistical analysis
--------------------

Continuous and categorical variables were expressed as median (IQR) and frequency counts (percent, %), respectively. The cut-off value of age for the prediction of OS was determined by mean value. Kaplan--Meier survival analysis was used to calculate the probability of OS, and survival differences were compared using the log-rank test. Associations of clinical and pathological characteristics with OS were evaluated using Cox proportional hazards regression models and summarized with HR and 95% CI. Univariate and multivariate Cox models were conducted. All *P*-values were corrected for multiple hypothesis testing, and false discovery rate (FDR)-corrected *P*-values (FDR-*P*) were used. The baseline variables with FDR*-P* \<0.05 in univariable analysis and variables reported clinical relevant in prior studies were included into the multivariate Cox proportional hazards regression model. Pathologic LNs stage and TNM stage were not included in the regression analysis because a majority of patients did not have LNs removed. A *P*-value \<0.05 was considered to represent a statistically significant difference; all reported *P*-values were two-sided. All analyses were conducted using SPSS 19.0 (SPSS Inc., Chicago, IL, USA). Figures were drawn by GraphPad Prism v.6 (GraphPad Software, Inc., La Jolla, CA, USA).

Results
=======

Baseline clinical and pathological characteristics
--------------------------------------------------

A total of 2,089 patients with RCC underwent surgery between January 2003 and September 2017 at our center. We identified 62 (3.0%) patients with histological element of SD after re-examining the available slides of suspicious cases; 53 patients, finally, were included in our study after we excluded 9 patients without adequate information of important variables and missed follow-up. The clinicopathological characteristics of the 53 patients are reported in [Table 1](#t1-cmar-10-5339){ref-type="table"}. All patients underwent radical or cytoreductive nephrectomy before pathological diagnosis. The median age (IQR) of the cohort was 53 (43--58) years; male patients were 1.21 fold of female patients in the cohort. A majority of patients had larger tumor size (median \[IQR\], 100 \[68--121\] mm), and more than half of the patients suffered symptoms of flank pain (56.6%) and hematuria (35.8%) at first presentation in patients with symptoms; 15.1% (8/53) patients had comorbidities of hypertension and/or diabetes mellitus; and the median Charlson Comorbidity Index was 5 (4--6) score. Approximately half of patients had local progressive disease (49.1% pT~3--4~), only 20 (37.7%) patients had regional LNs removed, and the rate of positive lymph nodes/negative lymph nodes (pN~1~/pN~0~) was 1.86:1 (13:7). 28.3% patients with cM1 were diagnosed. Lung and liver were the most common sites of metastasis. ccRCC accounted for 75.5% histological subtype, 71.7%, 68.0%, and 45.3% tumors showed necrosis, Ki-67 index of SD ≥30%, and %SD ≥25%, respectively.

Survival outcomes and stratification analysis
---------------------------------------------

The median OS for all patients was 11 months from the date of surgery ([Figure 1A](#f1-cmar-10-5339){ref-type="fig"}). In cM~0~ patients, the median OS was 21 months compared with only 3 months for cM~1~ patients ([Figure 1B](#f1-cmar-10-5339){ref-type="fig"}). Thirty-eight (71.7%) patients died at last followup, 33 of them died of cancer confirmed by death certificate, and the causes of another five patients were not verified and just knew the time of death from his or her families. Median length of follow-up for 15 survivals was 23.5 months (IQR: 13.5--62.25). Nine of thirty patients with negative or not assessed lymph-node (pN~0~/X) and cM~0~ presented metastasis-free survival, and the median duration of the follow-up was 65 months (IQR: 20.5--97) for this group. At least 13 of 38 cM~0~ patients observed local and/or distant recurrence with median of 5 months (IQR: 2.5--9). The most common site of postoperative metastases for patients with cM~0~ were lung (N=5), bone (N=3), intra-abdominal (N=3) and ipsilateral local (N=4). There were only three patients with cM~1~ treated with targeted therapy (sorafenib or sunitinib) after surgery; two of them refused the therapy contining because of adverse effects of the drugs, and another one died 4 months after surgery. Others did not receive systemic therapy in consideration of effects of drugs and financial burden, so just cytoreductive nephrectomy was performed for them for relief of symptoms. However, we were unable to confirm accurately the types of postoperative systemic therapy because a majority of patients who experienced disease advanced or tumor recurrence were managed in their local cancer center.

Overall, the 1-, 2-, and 5-year OS for the cohort was 43.5%, 34.2%, and 20.2%, respectively. The 1-, 2-, and 5-year OS for cM~0~ patients was 59.1%, 44.3%, and 26.1%, respectively, but 1-year OS for cM~1~ was only 26.7%. Advanced pT stage (pT~3~ and pT~4~) had a worse prognosis with median OS of 7 months in comparison with median OS of 27 months for stages pT~1~ and pT~2~ ([Figure 2A](#f2-cmar-10-5339){ref-type="fig"}). Ki-67 index and %SD with cut-off point of 30% and 25%, respectively, demonstrated significance in Kaplan--Meier survival analysis ([Figure 2B, C](#f2-cmar-10-5339){ref-type="fig"}). In contrast, the cohort of cM~0~ patients with Ki-67 index of SD ≥30% and ≥25% SD had significantly worse OS compared with Ki-67 index \<30% and\<25% SD ([Figure 3A, B](#f3-cmar-10-5339){ref-type="fig"}); however, in the cM~1~ setting, there was no observed difference ([Figure 3C, D](#f3-cmar-10-5339){ref-type="fig"}).

Predictors associated with prognosis
------------------------------------

Univariate and multivariate analyses were used to assess which clinicopathological features of 53 patients were associated with OS ([Table 2](#t2-cmar-10-5339){ref-type="table"}). In univariate analysis, age, gender, comorbidities of hypertension and diabetes mellitus, Charlson Comorbidity Index, ASA stage, and histological type were not associated with OS after *P*-values were corrected for multiple hypothesis testing with FDR-*P*. The variables found to be significant in the univariable analysis were further analyzed in the multivariate Cox model. In order not to miss underlying predictors, we also included the features of necrosis, histological types, and %SD in the model, although these variables were not statistically significant after multiple hypothesis testing; however, we found that no evidence of pathological features of tumor necrosis was significantly associated with OS in multivariate analysis. T stage, distant metastatic diseases, %SD, and Ki-67 index of SD were independent prognostic predictors. %SD with either 25% or 50% as a cut-off point did influence OS in univariate analysis. The same thing happened with Ki-67 index with either 30% or 50% as cut-off points, but both Ki-67 and %SD did not observe statistical significance when 50% was considered as a cut-off value in multivariate analysis. In addition, for cM~0~ patients, %SD and Ki-67 index of SD with 25% and 30% as cut-off points, respectively, were the two most important independent predictors for OS (*P*=0.0003 and *P*=0.002 for Ki-67 and %SD respectively, [Table 3](#t3-cmar-10-5339){ref-type="table"}). Meanwhile, we also found that in the cohort of cM~0~, symptom diseases were a predictor but tumor size and tumor stage were not associated with OS.

Discussion
==========

Fifty-three patients diagnosed with sRCC were analyzed in detail. Herein we again observed RCC with feature of SD have extremely poor outcomes. In our cohort, we observed only the median 11.0 months OS for all patients with metastases or not at diagnoses, what's more, only the median 21 months OS for cM~0~ patients. We observed that some patients benefited from surgery and showed prolonged progression-free survival.[@b1-cmar-10-5339],[@b6-cmar-10-5339] We hypothesized that a lower proliferative rate might contribute to a better prognostic outcome. Our data identified that %SD and Ki-67 index of SD were two independent predictors of OS, which might provide practical and clinical information of prognosis for clinicians to better counsel patients in the period of targeted therapy.

A majority of previous studies have attempted to risk stratify patients diagnosed with sRCC based on pathological features.[@b1-cmar-10-5339],[@b2-cmar-10-5339],[@b4-cmar-10-5339]--[@b6-cmar-10-5339] Similarly, a prior study that was reported by Kim et al[@b6-cmar-10-5339] also found this results, in cM~0~ setting, the tumors harboring much more %SD were more likely to suffer progression of disease and assert greater influence on OS. In their study, 50% as a cut-off point for %SD was not continue to analyzed when just found that 25% of SD can observed different influence on OS, in addition, Ki-67 index was not included in their study. Recently, Wang et al[@b23-cmar-10-5339] have shown the poor prognostic value of high Ki-67 index in RCC by meta-analysis. In the present study, we identified that the discrimination capability of either %SD or Ki-67 index was decreased when the cut-off point increased to 50%, which informed us that there might be another better cut-off point for a better discrimination of prognostic outcomes in the interval of 25%--50% for %SD and 30%--50% for Ki-67 index. Another study by Zhang et al[@b1-cmar-10-5339] increased the cut-off point of %SD to 30%, and indicated patients with tumors presenting ≥30% of SD were 52% more likely to die from sRCC than those with tumors with element of SD \<30%, but they did not stratify patients based on the distant metastatic diseases (cM~1~ and cM~0~). We found that neither %SD nor Ki-67 index was associated with OS for patients without distant metastatic diseases but not for the cM~1~ cohort, which was consistent with Kim et al.[@b6-cmar-10-5339] In addition, some studies found that the amount of SD impacts response to therapy. It has been reported that RCCs with \<20% SD have partial response to targeted therapy, and those with higher amounts of SD are more likely to respond to cytotoxic chemotherapy consisting of doxorubicin and gemcitabine.[@b17-cmar-10-5339],[@b24-cmar-10-5339]

In our study, we also want to investigate whether there exists different influence between histological types on OS. But, in the present study, we did not find that histological types of RCC could reach statistical significance. To our knowledge, the utility of histological types as a predictor remains controversial. The histological features of SD can be observed in all types of RCC[@b25-cmar-10-5339]; ccRCC is the most common histological subtype, which accounts for about 65%--79% of all histological subtype with sarcomatoid dif ferentiation.[@b1-cmar-10-5339],[@b2-cmar-10-5339],[@b5-cmar-10-5339]--[@b8-cmar-10-5339],[@b18-cmar-10-5339] Nguyen et al[@b2-cmar-10-5339] showed that histological subtype was associated with cancer-specific survival (*P*=0.001) but not associated with distant metastasis (*P*=0.8) in patients with sRCC and found that patients with ncRCCs were more likely to die from sRCC (HR: 2.3: 95% CI: 1.38--3.82) than ccRCC. In the targeted therapy period, Golshayan et al[@b17-cmar-10-5339] found that patients with metastatic sRCC with underlying histological subtype of ccRCC were more likely to respond to VEGF-targeted therapy. Conversely, Cheville et al[@b26-cmar-10-5339] showed that ccRCC and chromophobe RCC were more likely to have tumors with SD (5.2% and 8.7%, respectively), but the underlying histological subtype of sRCC was not a prognostic predictor.

There are some limitations to our study. First, the retrospective design and small sample size in this single center study were unable to further stratify prognostic predictors (eg, tumor stage, histological subtypes, etc). Although the long follow-up time was accrued over 15 years, 89% patients with sRCC were referred to our center after 2010 and the similar technique of radical nephrectomy was performed for all patients. In addition, regional retroperitoneal LN dissection was not routinely performed and was determined by the operating surgeon at nephrectomy; however, a standard of the extent of LN dissection was still not identified, and most of prior studies were also not well evaluated. The findings should be validated in a larger cohort and should identify a better cut-off point.

Conclusion
==========

SD is associated with a very poor prognosis for patients with RCC regardless of metastasis, as reported in this single institution analysis of 52 cases. Although underlying subtype of ccRCC and ncRCC and necrosis features did not reach statistical significance, the tumor features with higher proliferation rate including Ki-67 index of SD ≥30% and %SD ≥25% were associated with higher risk of death from sRCC and identified two most important independent predictors. The limitations of our study were also observed, and further studies are needed.
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![Kaplan--Meier survival curves for overall survival.\
**Notes:** (**A**) Fifty-three patients with sarcomatoid renal cell carcinoma after nephrectomy and stratified by (**B**) status of clinical distant metastasis.\
**Abbreviations:** cM~0~, no clinical distant metastasis; cM~1~, clinical distant metastasis.](cmar-10-5339Fig1){#f1-cmar-10-5339}

![Kaplan--Meier survival curves for overall survival stratified by (**A**) tumor stage, (**B**) Ki-67 index of SD, and (**C**) %SD.\
**Abbreviations:** SD, sarcomatoid differentiation; %SD, percent of SD.](cmar-10-5339Fig2){#f2-cmar-10-5339}

![Overall survival in patients with Ki-67 index and %SD for (**A, B**) cM~0~ groups and (**C, D**) cM~1~ groups.\
**Abbreviations:** cM~0~, no clinical distant metastasis; cM~1~, clinical distant metastasis; SD, sarcomatoid differentiation; %SD, percent of SD.](cmar-10-5339Fig3){#f3-cmar-10-5339}

###### 

Clinicopathological characteristics of patients with sarcomatoid renal cell carcinoma (N=53)

  Variables                                                                 No. of patients or median (IQR)   \%
  ------------------------------------------------------------------------- --------------------------------- ------
  **Clinical characteristics**                                                                                
  Sex                                                                                                         
   Male                                                                     29                                54.7
   Female                                                                   24                                45.3
  Age (years) median (range)                                                53 (43--58)                       
   \<50                                                                     22                                41.5
   ≥50                                                                      31                                58.5
  BMI (kg/m^2^), median (range)                                             21.3 (19.5--23.3)                 
  Symptomatic at presentation                                                                                 
   No                                                                       12                                22.6
   Yes                                                                      41                                77.4
  Symptoms[a](#tfn1-cmar-10-5339){ref-type="table-fn"}                                                        
   Pain                                                                     30                                56.6
   Hematuria                                                                19                                35.8
   Fatigue and/or weakness                                                  9                                 17.0
   Fever and/or night sweats                                                8                                 15.1
   Weight loss                                                              4                                 7.5
   Mass of abdomen                                                          8                                 15.1
  Comorbidities (HP and/or DM)                                                                                
   No                                                                       45                                84.9
   Yes                                                                      8                                 15.1
  ASA score                                                                                                   
   1 and 2                                                                  42                                79.2
   3 and 4                                                                  10                                18.9
  Charlson Comorbidity Index                                                5 (4--6)                          
  **Tumor characteristics**                                                                                   
  Tumor size (mm)                                                           100 (68--121)                     
  T -- pathological tumor stage                                                                               
   pT1a                                                                     2                                 3.8
   pT1b                                                                     11                                20.8
   pT2a                                                                     7                                 13.2
   pT2b                                                                     7                                 13.2
   pT3a                                                                     15                                28.3
   pT3b                                                                     2                                 3.8
   pT3c                                                                     2                                 3.8
   pT4                                                                      7                                 13.2
  N -- regional lymph nodes                                                                                   
   pN~X~                                                                    33                                62.3
   pN~0~                                                                    7                                 13.2
   pN~1~                                                                    13                                24.5
  M -- distant metastasis                                                                                     
   cM~0~                                                                    38                                71.7
   cM~1~                                                                    15                                28.3
  Sites of metastatic disease[a](#tfn1-cmar-10-5339){ref-type="table-fn"}                                     
   Lung                                                                     5                                 33.3
   Liver                                                                    4                                 26.7
   Bone                                                                     2                                 13.3
   Adrenal gland                                                            2                                 13.3
   Other                                                                    3                                 20.0
  Enlarged lymph nodes in imaging                                                                             
   No                                                                       32                                60.4
   Yes                                                                      21                                39.6
  **Histological characteristics**                                                                            
  Predominant cell type                                                                                       
   Clear cell                                                               40                                75.5
   Papillary                                                                3                                 5.7
   Chromophobe                                                              4                                 7.5
   Collecting duct                                                          1                                 1.9
   Mucinous cell                                                            1                                 1.9
   Uncertain                                                                4                                 7.5
  Ki-67 index of SD                                                                                           
   %Ki-67\<30%                                                              17                                32.1
   30%≤%Ki-67\<50%                                                          10                                18.9
   %Ki-67≥50%                                                               26                                49.1
  Percent of SD                                                                                               
   %SD\<25%                                                                 29                                54.7
   25%≤%SD\<50%                                                             13                                24.5
   %SD≥50%                                                                  11                                20.8
  Tumor necrosis                                                                                              
   Yes                                                                      38                                71.7
   No                                                                       15                                28.3

**Note:**

Several patients had more than one symptom and metastatic site at presentation.

**Abbreviations:** ASA, American Society of Anesthesiologists; BMI, body mass index; cM~0,~ no clinical distant metastasis; cM~1,~ clinical distant metastasis; DM, diabetes mellitus; HP, hypertension; pN~x~, not assessed lymph-node; pT, pathological tumor stage; SD, sarcomatoid differentiation, %SD, percent of SD.

###### 

Results of univariate and multivariate analyses of overall survival (N=53)

  Variables                                                                                                                                    Univariate           Multivariate[\*\*](#tfn5-cmar-10-5339){ref-type="table-fn"}                        
  -------------------------------------------------------------------------------------------------------------------------------------------- -------------------- ------------------------------------------------------------- -------------------- -------
  Female gender (reference: male)                                                                                                              1.60 (0.84--3.06)    0.221                                                                              
  Age ≥50 years (reference: \<50 years)                                                                                                        2.12 (1.06--4.23)    0.088                                                                              
  Symptomatic disease (reference: incidental diagnosis)                                                                                        3.50 (1.34--9.12)    0.033                                                         2.78 (0.98--7.87)    0.055
  Comorbidities: HP and/or DM (reference: no)                                                                                                  0.82 (0.32--2.11)    0.682                                                                              
  ASA stage: 3--4 (reference: 1--2)                                                                                                            1.68 (0.79--3.60)    0.213                                                                              
  Charlson Comorbidity Index                                                                                                                   1.26 (0.99--1.61)    0.113                                                                              
  T stage: pT~1--2~ (reference: pT~3--4~)                                                                                                      3.04 (1.49--6.19)    0.010                                                         2.93 (1.40--6.11)    0.042
  Clinical distant metastasis: cM~1~ (reference: cM~0~)                                                                                        3.72 (1.79--7.75)    0.003                                                         2.93 (1.33--6.44)    0.008
  Enlarged lymph nodes in imaging (reference: no)                                                                                              1.59 (0.82--3.07)    0.221                                                                              
  Histological types: nonclear cell (reference: clear cell)                                                                                    0.75 (0.39--1.44)    0.415                                                         0.56 (0.21--1.49)    0.247
  Tumor necrosis (reference: no)                                                                                                               2.06 (1.00--4.40)    0.104                                                         1.72 (0.74--4.00)    0.209
  **Results from different inclusion of threshold value for %SD and % Ki-67 together with all other variables according to the above model**                                                                                                           
  %SD≥25% (reference: %SD\<25%)                                                                                                                2.04 (1.05--3.85)    0.078                                                         2.62 (1.27--5.41)    0.009
  %SD≥50% (reference: %SD\<50%)                                                                                                                2.45 (1.17--5.10)    0.017                                                         1.81 (0.84--3.88)    0.129
  Ki-67 index of SD/5%[\*\*\*1](#tfn6-cmar-10-5339){ref-type="table-fn"}                                                                       1.174 (1.03--1.40)   0.016                                                         1.21 (1.03--1.43)    0.020
  Ki-67 index of SD: ≥30% (reference: \<30%)[\*\*\*2](#tfn7-cmar-10-5339){ref-type="table-fn"}                                                 6.163 (2.34--16.2)   0.003                                                         4.39 (1.63--11.82)   0.003
  Ki-67 index of SD: ≥50% (reference: \<50%)[\*\*\*3](#tfn7-cmar-10-5339){ref-type="table-fn"}                                                 5.90 (2.58--13.50)   0.0003                                                        2.46 (0.98--6.15)    0.055

**Notes:** Lymph nodes status and TNM stage were not included in the multivariate model because of the high number of patients who did not have lymph nodes removed.

All *P*-values were corrected for multiple hypothesis testing with false discovery rate (FDR)-corrected *P*-values (FDR-*P*).

Variables with FDR-*P* \<0.05 and clinically relevant factors were included in multivariate analysis.

Continuous variable.

Categorical variable.

**Abbreviations:** ASA, American Society of Anesthesiologists; cM~0~, no clinical distant metastasis; cM~1~, clinical distant metastasis; DM, diabetes mellitus; HP, hypertension; SD, sarcomatoid differentiation; %SD, percent of SD.

###### 

Results of multivariate analysis of overall survival for cM~0~ patients (N=38)

  Variables                                                                          HR (95% CI)         *P*-value
  ---------------------------------------------------------------------------------- ------------------- -----------
  %SD≥25% (reference: %SD\<25%)                                                      4.22 (1.74--10.2)   0.002
  Ki-67 index of SD: ≥30% (reference: \<30%)                                         8.34 (2.62--26.5)   0.0003
  Tumor size (mm)[a](#tfn9-cmar-10-5339){ref-type="table-fn"}                        1.00 (0.98--1.01)   0.428
  T stage: pT~1~ (reference: pT~2--4~)[a](#tfn9-cmar-10-5339){ref-type="table-fn"}   3.11 (0.66--14.7)   0.153
  T stage: pT (reference: pT a 1--2 3--4)                                            2.30 (0.91--5.81)   0.077

**Note:**

Variable with different threshold was put into multivariate Cox regression analysis respectively together with all other variables in one model.

**Abbreviations:** cM~0,~ no clinical distant metastasis; SD, sarcomatoid differentiation; %SD, percent of SD.
